More positive results from our MDMA-analogue screening program, aimed at developing a library of MDMA-like compounds that can form the basis for a future psychiatric treatment, harnessing the potency of MDMA but reducing or eliminating the existing side effects.
16 more compounds have demonstrated no interaction with the receptors and enzymes that cause known side effects, bringing the number of successfully screened compounds to 83.
